Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-06-30 pm EDT
142.85 USD   +0.03%
05:34pUS FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
RE
04:40pTweaked COVID boosters in US must target newer omicron types
AQ
04:36pModerna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global News
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1 HIV Vaccine Trial in Africa

05/18/2022 | 08:10am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
DOW JONES AFRICA TITANS 50 INDEX -1.33% 447.07 Real-time Quote.-15.38%
DOW JONES SOUTH AFRICA(ZAR) 0.00% 1858.13 Real-time Quote.-4.58%
IMMUNOGEN, INC. 3.21% 4.5 Delayed Quote.-39.35%
MODERNA, INC. 0.03% 142.85 Delayed Quote.-43.76%
S&P AFRICA 40 INDEX -0.04% 143.83 Real-time Quote.-16.23%
All news about MODERNA, INC.
05:34pUS FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
RE
04:40pTweaked COVID boosters in US must target newer omicron types
AQ
04:36pModerna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global New..
RE
02:22pCOVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna..
RE
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
RE
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
RE
06/28Pfizer, Moderna to be ready with BA.1-specific COVID boosters
RE
06/28FDA advisers recommend updating COVID booster shots for fall
AQ
06/27INSIDER SELL : Moderna
MT
06/27US grapples with whether to modify COVID vaccine for fall
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 079 M - -
Net income 2022 11 509 M - -
Net cash 2022 18 531 M - -
P/E ratio 2022 5,24x
Yield 2022 -
Capitalization 56 820 M 56 820 M -
EV / Sales 2022 1,73x
EV / Sales 2023 3,48x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 142,85 $
Average target price 213,67 $
Spread / Average Target 49,6%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-43.76%56 804
IQVIA HOLDINGS INC.-24.11%40 527
LONZA GROUP AG-33.77%39 234
SEAGEN INC.15.82%32 961
CELLTRION, INC.-9.85%18 726
ICON PUBLIC LIMITED COMPANY-29.85%17 663